Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...

Under the settlement, Mainers who are uninsured or have commercial health insurance will be eligible to purchase monthly ...

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.

While long-acting insulin is slow to reach the bloodstream and has a relatively low peak, it stabilizes the “plateau” effect on blood sugar that can last most of the day. Glargine or Lantus is ...

Food that can support insulin sensitivity include non-starchy vegetables, whole grains, and citrus fruits. People with insulin resistance may also wish to limit sugary drinks and highly processed ...

Merilog is available in a 3 mL prefilled pen and a 10 mL vial, joining two long-acting insulin biosimilars approved by the FDA in 2021. Merilog, a rapid-acting human insulin analog, is the first ...

The FDA previously approved two long-acting insulin biosimilars, Mylan Pharmaceuticals’ Semglee in June 2020 and Lilly’s glargine biosimilar, Rezvoglar in December 2021. Merilog is approved as ...

Merilog 100units/mL is supplied as both a 10mL multi-dose vial as well as a 3mL single-patient-use prefilled pen. The Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj ...

Insulin overdose symptoms can include confusion, fatigue, irritability, shaking, and other signs of low blood sugar (hypoglycemia). If you accidentally take too much or your blood sugar is low for ...

1 Merilog is the third overall insulin biosimilar to receive approval, following 2 insulin glargine biosimilars: Semglee (insulin glargine-yfgn) and Rezvoglar (insulin glargine-aglr). 2 “The FDA has ...

When Semglee (insulin glargine-yfgn, Biocon/Mylan) was approved in July of 2021, it was noted that this would be the first glargine biosimilar that was interchangeable with Lantus (Sanofi ...

Although Lantus continues to lead the insulin glargine market globally, the rise of biosimilars like Abasaglar and Semglee has sparked significant price reductions, with some European countries seeing ...